Scientists have determined the molecular target and mechanism of the antibacterial drug fidaxomicin (trade name Dificid). Fidaxomicin was approved in 2011 for treatment of the CDC 'urgent threat' bacterial pathogen Clostridium difficile (C. diff) and currently is one of two front-line drugs for treatment of C. diff.
Target and mechanism of antibacterial drug fidaxomicin (Dificid) discovered
Science Daily - 29 Mar 2018 20:10
Scientists have determined the molecular target and mechanism of the antibacterial drug fidaxomicin (trade name Dificid). Fidaxomicin was approved in 2011 for treatment of the CDC 'urgent threat' bacterial pathogen Clostridium difficile (C. diff) and currently is one of two front-line drugs for treatment of C. diff.
Share this Article
Recommended